ROR1 and non-small cell lung carcinoma: Analysis of RNA-seq data from GSE135222 (from 27 NSCLC patients treated with anti-PD1/PD-L1) revealed significantly higher ROR1 mRNA levels in patients resistant to ICB than in patients who benefit from ICB treatment (p < 0.01) (Fig. 1A).